Novel Strategy to Ameliorate Pulmonary Hypertension: A Combination of Angiogenic Factors and Vascular Stabilizing Factors to Generate Proper-Structured and Effectively-Perfused Pulmonary Arterioles

2020 ◽  
Author(s):  
Haoran Miao ◽  
Fan Qiu ◽  
Lidong Zhu ◽  
Bo Jiang ◽  
Xiucheng Liu ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Angiogenic Factors ◽  
Novel Strategy ◽  
Stabilizing Factors

scholarly journals Increased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary Hypertension

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0159005 ◽  
Author(s):  
Csaba Galambos ◽  
Angela D. Minic ◽  
Douglas Bush ◽  
Dominique Nguyen ◽  
Blair Dodson ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Down Syndrome ◽  
Potential Role ◽  
Angiogenic Factors ◽  
Vascular Growth

scholarly journals L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infants

2014 ◽  
Vol 103 (10) ◽  
pp. 1019-1026 ◽  
Author(s):  
Candice D. Fike ◽  
Marshall Summar ◽  
Judy L. Aschner
Keyword(s):  
Pulmonary Hypertension ◽  
Newborn Infants ◽  
Chronic Pulmonary Hypertension ◽  
Novel Strategy

The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases

2019 ◽  
Vol 3 (1) ◽  
pp. 97-105
Author(s):  
Mary Zuccato ◽  
Dustin Shilling ◽  
David C. Fajgenbaum
Keyword(s):  
Rare Diseases ◽  
Treatment Options ◽  
Castleman Disease ◽  
High Impact ◽  
Collaborative Network ◽  
Network Approach ◽  
Grant Applications ◽  
Research Questions ◽  
Novel Strategy ◽  
Patient Centric

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.

Design and Optimization of a Novel Strategy for the Local Treatment of Helicobacter pylori Infections

2020 ◽  
Author(s):  
Taddese Mekonnen Ambay ◽  
Philipp Schick ◽  
Michael Grimm ◽  
Maximilian Sager ◽  
Felix Schneider ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Local Treatment ◽  
Design And Optimization ◽  
Novel Strategy

Porto-pulmonary hypertension in decompensated cirrhosis and refractory ascites

2001 ◽  
Vol 120 (5) ◽  
pp. A377-A377
Author(s):  
F BENJAMINOV ◽  
K SNIDERMAN ◽  
S SIU ◽  
P LIU ◽  
M PRENTICE ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Refractory Ascites ◽  
Decompensated Cirrhosis
Sign in / Sign up

Export Citation Format

Share Document